Google Ad

Bayer to pay $1.6 bn to settle US claims over contraception gadget

Bayer’s settlement over Essure within the United States impacts round 90 % of the claims filed within the nation

Pharmaceutical large Bayer introduced Thursday it had agreed to pay $1.6 billion to settle practically all claims filed within the United States over controversial contraception implant Essure.

“The company will pay approximately $1.6 billion to resolve these claims, including an allowance for outstanding claims, and is in resolution discussions with counsel for the remaining plaintiffs,” the German firm mentioned in a press release.

“There is no admission of wrongdoing or liability by Bayer in the settlement agreements,” the assertion mentioned, and the settlement doesn’t apply to claims filed in different nations.

Essure, a non-hormonal coil implant used to stop being pregnant, has in some circumstances precipitated persistent ache, perforation of the uterus and fallopian tubes and led to hysterectomies, information experiences say. It was discontinued in 2018.

Approved within the United States in 2002, the gadget’s perceived benefit is that it’s a much less invasive different to tubal litigation, by which a small gap is minimize into the stomach and the surgeon blocks or cuts the fallopian tube.

Bayer’s pharmaceutical division mentioned within the second quarter it took a cost of 1.25 billion euros for litigation, primarily for claims round Essure.

All instructed, Bayer reported a lack of 9.55 billion euros in that quarter, which was largely reflective of a US settlement of hundreds of claims that its glyphosate weed killer could have precipitated most cancers.

Bayer to finish non-US gross sales of Essure, a contested sterilisation implant

© 2020 AFP

Bayer to pay $1.6 bn to settle US claims over contraception gadget (2020, August 20)
retrieved 20 August 2020

This doc is topic to copyright. Apart from any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.

Latest Updates

Related Post